Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 10Sarcoma 1

Conditions

Sarcoma 69Osteosarcoma 29Sarcoma, Ewing 20Rhabdomyosarcoma 17Ovarian Neoplasms 17Melanoma 17Neuroblastoma 15Gastrointestinal Stromal Tumors 15Colorectal Neoplasms 12Bone Neoplasms 12Wilms Tumor 11Sarcoma, Kaposi 11Rhabdoid Tumor 11Neoplasms 11Lymphoma, Non-Hodgkin 10Hepatoblastoma 10Glioma 10Breast Neoplasms 10Stomach Neoplasms 9Medulloblastoma 9Liposarcoma 9Ependymoma 9Neurofibrosarcoma 8Neuroectodermal Tumors, Primitive, Peripheral 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Prostatic Neoplasms 7Pancreatic Neoplasms 7

Interventions

Eflornithine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × Sarcoma × 30 days × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡